Article Text
Abstract
New guidelines have been produced for the management of primary biliary cholangitis, an infrequent but nonetheless important autoimmune liver disease. We provide a succient commentary and overview of the key features of disease management that arise from these recent guideline recommendations, with a focus on therapy with licensed agents (ursodeoxycholic acid and obeticholic acid) as well as personalised management of disease complications and associated symptoms.
- cholestasis
- primary biliary cirrhosis
- ursodeoxycholic acid
- obeticholic acid
Statistics from Altmetric.com
Footnotes
Contributors Drafting the manuscript: JCG. Drafting and revising the manuscript critically for important intellectual content: GMH.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests GMH has consulted for GSK, Novartis, Cymabay, Intercept, Falk, Gilead.
Provenance and peer review Not commissioned; externally peer reviewed.